CN106478618A - The preparation method of emtricitabine halogen acid salt - Google Patents

The preparation method of emtricitabine halogen acid salt Download PDF

Info

Publication number
CN106478618A
CN106478618A CN201610898062.8A CN201610898062A CN106478618A CN 106478618 A CN106478618 A CN 106478618A CN 201610898062 A CN201610898062 A CN 201610898062A CN 106478618 A CN106478618 A CN 106478618A
Authority
CN
China
Prior art keywords
emtricitabine
acid salt
preparation
halogen acid
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610898062.8A
Other languages
Chinese (zh)
Inventor
应述欢
皮红军
王亮
刘胜辉
陈健
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Bocimed Pharmaceutical Co Ltd
Original Assignee
Shanghai Li Tai Pharmaceutical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Li Tai Pharmaceutical Technology Co Ltd filed Critical Shanghai Li Tai Pharmaceutical Technology Co Ltd
Priority to CN201610898062.8A priority Critical patent/CN106478618A/en
Publication of CN106478618A publication Critical patent/CN106478618A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D411/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Saccharide Compounds (AREA)

Abstract

The invention discloses the preparation method of emtricitabine halogen acid salt.The invention provides a kind of preparation method of emtricitabine halogen acid salt, it comprises the following steps:In alcohols solvent, emtricitabine crude product and hydrogen halides are carried out salt-forming reaction, obtains emtricitabine halogen acid salt;The HPLC purity of described emtricitabine crude product is more than 85.0%;Described hydrogen halides are hydrogen chloride, hydrogen bromide or hydrogen iodide, and X is chlorine, bromine or iodine.The preparation method of the present invention is simple to operate, post processing is easy, high income, prepared emtricitabine product purity high, can reach crude drug standard, HPLC purity is more than 99.60%, maximum single contaminant and is less than 0.10% low production cost, is suitable for industrialized production.

Description

The preparation method of emtricitabine halogen acid salt
Technical field
The present invention relates to the preparation method of emtricitabine halogen acid salt.
Background technology
Emtricitabine I (Emtriva, FTC) combines controlling for HIV-1 infection of being grown up with other antiretroviral drugs Treat.Emtricitabine I is a kind of novel nucleoside reverse transcriptase inhibitors, all has antiviral activity to HIV-1, HIV-2 and HBV. This product is phosphorylated to the 5 '-triphosphate with cytoactive after being administered orally, 5 '-triphosphate passes through to enter viral DNA main chain, Be combined with main chain, lead to chain termination, thus suppressing HIV1-RT and HBV-DNA polymerase activity.Emtricitabine I structure Shown in formula I:
The method preparing emtricitabine I under the conditions of prior art is all to be obtained by the reaction of emtricitabine intermediate III, due to Emtricitabine I has larger water solublity, and the crude product that post processing obtains contains a large amount of inorganic salts, thus cannot direct crystallization purification, Need to carry out post separation ability purification, operating condition is loaded down with trivial details, expend a large amount of materials, is unfavorable for industrialized production.It is thus desirable to seeking Look for a kind of simple to operate, post processing is easy, high income, prepared product purity height can reach crude drug standard, production cost The preparation method of emtricitabine that is low, being suitable for industrialized production.
Content of the invention
The technical problem to be solved is to overcome the operation of the preparation method of emtricitabine in prior art multiple Miscellaneous, post-processing approach is complicated, production cost is high, be not suitable for the defects such as industrialized production and provide a kind of emtricitabine hydrogen halogen The preparation method of hydrochlorate.The preparation method of the present invention is simple to operate, post processing is easy, high income, prepared emtricitabine product Purity height can reach crude drug standard, low production cost, be suitable for industrialized production.
The invention provides a kind of preparation method of emtricitabine halogen acid salt, it comprises the following steps:In alcohols solvent In, emtricitabine crude product and hydrogen halides are carried out salt-forming reaction, obtains emtricitabine halogen acid salt;Described emtricitabine The HPLC purity of crude product is more than or equal to 85.0%;Described hydrogen halides are hydrogen chloride, hydrogen bromide or hydrogen iodide;X be chlorine, bromine or Iodine;
In the preparation method of described emtricitabine halogen acid salt, the preferred methanol of described alcohols solvent, ethanol, isopropyl One or more of alcohol and the tert-butyl alcohol;Further preferably isopropanol.
In the preparation method of described emtricitabine halogen acid salt, described emtricitabine crude product is molten with described alcohols The mass volume ratio value preferably 1: 1g/mL~1: 30g/mL of agent, further preferred 1: 5g/mL~1: 20g/mL;Such as 1: 10g/ mL.
In the preparation method of described emtricitabine halogen acid salt, the preferred hydrogen chloride of described hydrogen halides or hydrogen bromide. In the form of can be for the alcoholic solution of hydrogen chloride gas or hydrogen chloride when using hydrogen chloride;When using ethanolic hydrogen chloride solution, Preferred 1mol/L~the 3mol/L of concentration, such as 2mol/L of described ethanolic hydrogen chloride solution.It can be bromine when using hydrogen bromide Change the form of the alcoholic solution of hydrogen;When using hydrogen bromide alcoholic solution, the preferred 1mol/L of concentration of described hydrogen bromide alcoholic solution~ 3mol/L, such as 2mol/L.
In the preparation method of described emtricitabine halogen acid salt, described hydrogen halides and described emtricitabine crude product Molar ratio preferably 1~1.2, further preferred 1~1.1, such as 1.0.
In the preparation method of described emtricitabine halogen acid salt, preferably -20 DEG C of the temperature of described salt-forming reaction~ 30 DEG C, further preferred 0 DEG C~30 DEG C, such as 10 DEG C~20 DEG C.
In the preparation method of described emtricitabine halogen acid salt, preferably 1 hour time of described salt-forming reaction~ 10 hours, further preferred hour 1~5 hour, such as 2 hours.
The preparation method of described emtricitabine halogen acid salt, it is preferred to use following steps:The alcoholic solution of hydrogen halides is added Enter in the solution being formed with alcohols solvent to emtricitabine crude product, carry out salt-forming reaction, obtain emtricitabine halogen acid salt. The preferred Deca of mode of described addition, the speed preferred 1mL/ minute~50mL/ minute of Deca, such as 20mL/ minute~ 30mL/ minute.
The preparation method of described emtricitabine halogen acid salt, preferably includes following post-processing step:After reaction terminates, mistake Filter, wash, being dried to obtain emtricitabine halogen acid salt.
Described being filtered, washed and dried can be using the conventional method of this generic operation in this area.Described drying is excellent Choosing vacuum drying;Preferably 40 DEG C~60 DEG C of described vacuum drying temperature, such as 60 DEG C;The described vacuum drying time is excellent Select 1 hour~10 hours, further preferred 2 hours~6 hours, such as 4 hours~5 hours;Described vacuum drying pressure Preferably -0.08MPa~-0.1MPa.
The preparation method of described emtricitabine halogen acid salt, preferably further includes following post-processing step:To obtain Emtricitabine halogen acid salt be recrystallized to give emtricitabine halogen acid salt after purification.
In the further preferred post-processing step of the preparation method of emtricitabine halogen acid salt, described recrystallization is permissible Conventional method using this generic operation in this area.The preferred alcohols solvent of solvent that described recrystallization adopts, alcohols solvent with The mixed solvent of ether solvent or the mixed solvent of alcohols solvent and esters solvent.The preferred methanol of described alcohols solvent, ethanol, One of isopropanol and the tert-butyl alcohol or many.The preferred diisopropyl ether of described ether solvent, dioxane, oxolane, 2- methyl One or more of oxolane and n-butyl ether.Described esters solvent ethyl acetate and/or isopropyl acetate.When adopting During with the mixed solvent of alcohols solvent and ether solvent, described ether solvent is preferred with the volume ratio of described alcohols solvent 1~2;Such as 1.6 or 1.3.The further preferred methanol of mixed solvent of described alcohols solvent and ether solvent and diisopropyl ether Mixed solvent or the mixed solvent of ethanol and 2- methyltetrahydrofuran.When the mixed solvent using alcohols solvent and esters solvent When, the volume ratio preferably 1~2, such as 1 or 1.7 of described esters solvent and described alcohols solvent;Described alcohols solvent The mixed solvent of further preferred isopropanol and isopropyl acetate or ethanol and ethyl acetate with the mixed solvent of esters solvent Mixed solvent.
In the post-processing step that the preparation method of emtricitabine halogen acid salt preferably further includes, described alcohols is molten The mixed solvent of the mixed solvent of agent, alcohols solvent and ether solvent or alcohols solvent and esters solvent and described emtricitabine The mass volume ratio value preferably 1: 1g/mL~1: 30g/mL of halogen acid salt, further preferred 1: 2g/mL~1: 20g/mL;Such as 1 : 5g/mL, 1: 10g/mL, 1: 13g/mL, 1: 14g/mL or 1: 16g/mL.
In the post-processing step that the preparation method of emtricitabine halogen acid salt preferably further includes, described recrystallization Preferably 50 DEG C~80 DEG C of temperature, further preferred 55 DEG C~70 DEG C, such as 55 DEG C~65 DEG C or 60 DEG C~70 DEG C.
In the post-processing step that the preparation method of emtricitabine halogen acid salt preferably further includes, described recrystallization Preferably employ following steps 1 or step 2:
Step 1:Emtricitabine halogen acid salt is dissolved in alcohols solvent, adds ether solvent or esters solvent, cold But crystallize obtains emtricitabine halogen acid salt after purification;
Step 2:Emtricitabine halogen acid salt is dissolved in alcohols solvent, then cooling crystallization obtain grace after purification bent he Shore halogen acid salt.
In step 1 or step 2, preferably 50 DEG C~80 DEG C of the temperature of described dissolving, further preferred 55 DEG C~70 DEG C, example As 55 DEG C~65 DEG C or 60 DEG C~70 DEG C.
In step 1 or step 2, preferably 0 DEG C~20 DEG C of the temperature of described cooling crystallization, further preferred 5 DEG C~15 DEG C, Such as 5 DEG C~10 DEG C or 10 DEG C~15 DEG C.Preferably 1 hour~5 hours time of described cooling crystallization, further preferred 1 is little When~3 hours, such as 1 hour.
In step 1 or step 2, described dissolving and cooling crystallization are preferably carried out under conditions of stirring, described stirring Preferably 60 revs/min~120 revs/min of speed, such as 60 revs/min, 80 revs/min, 90 revs/min, 100 revs/min Or 120 revs/min.
The preparation method of described emtricitabine halogen acid salt, also includes still further preferably after recrystallization filtering, washs Step with being dried.
In the step that the preparation method of emtricitabine halogen acid salt still further preferably includes, described filtration, washing Can be using the conventional method of this generic operation in this area with drying.Described washs the preferred alcohols solvent of solvent adopting, ether Class solvent or esters solvent;The preferred diisopropyl ether of described ether solvent, dioxane, oxolane, 2- methyltetrahydrofuran and One or more of n-butyl ether.Described esters solvent ethyl acetate and/or isopropyl acetate.Described alcohols solvent The preferably tert-butyl alcohol.The number of times of described washing preferably 1 time~3 times, such as 2 times.Described drying is preferably vacuum dried;Described Preferably 40 DEG C~60 DEG C of vacuum drying temperature, such as 50 DEG C~60 DEG C;The described vacuum drying time preferably 1 hour~10 Hour, further preferred 2 hours~6 hours, such as 4 hours~8 hours;Described vacuum drying pressure preferably -0.08MPa ~-0.1MPa.
Present invention also offers a kind of preparation method of emtricitabine, it comprises the following steps:In alcohols solvent, will be upper The emtricitabine halogen acid salt that method of stating is obtained is neutralized reaction with organic base, obtains emtricitabine;X be chlorine, bromine or Iodine;
In the preparation method of described emtricitabine, the preferred methanol of described alcohols solvent, ethanol, isopropanol and tertiary fourth One or more of alcohol;Further preferably methanol.
In the preparation method of described emtricitabine, described emtricitabine halogen acid salt and described alcohols solvent Mass volume ratio value preferably 1: 1g/mL~1: 20g/mL, further preferred 1: 2g/mL~1: 10g/mL;Such as 1: 5g/mL or 1: 8g/mL.
In the preparation method of described emtricitabine, the preferred triethylamine of described organic base and/or N, N- diisopropyl Ethylamine.
In the preparation method of described emtricitabine, described organic base is rubbed with described emtricitabine halogen acid salt That ratio preferably 1~2;Further preferred 1~1.5;Such as 1,1.2 or 1.4.
In the preparation method of described emtricitabine, preferably 0 DEG C~40 DEG C of the temperature of described neutralization reaction, further Preferably 10 DEG C~30 DEG C, such as 15 DEG C~25 DEG C.
In the preparation method of described emtricitabine, preferably 1 hour~5 hours time of described neutralization reaction, enter One step preferably 1 hour~3 hours, such as 1 hour.
The preparation method of described emtricitabine preferably employs following steps:To emtricitabine halogen acid salt and alcohols solvent In the mixture being formed, add organic base, be neutralized reaction and obtain described emtricitabine.
The preferred Deca of mode of described addition;The speed of described Deca preferably 1 gram/minute~30 gram/minute, for example 3.6 gram/minute~5.5 gram/minute, 7.8 gram/minute~10.3 gram/minute or 9.3 gram/minute~14.0 gram/minute.
The preparation method of described emtricitabine preferably employs following post-processing step:After reaction terminates, remove solvent and obtain To emtricitabine.The mode of the described removing preferred vacuum distillation of solvent.
The preparation method of described emtricitabine further preferably adopts following post-processing step:By the emtricitabine obtaining Making beating, filters, and washing is dried, obtains emtricitabine after purification.
Described making beating can be excellent using the conventional method of this generic operation in this area, the solvent of described making beating and washing Select halogenated hydrocarbon solvent, the preferred chlorinated hydrocarbon solvent of described halogenated hydrocarbon solvent;The preferred dichloro of described chlorinated hydrocarbon solvent Methane.Preferably 20 DEG C~25 DEG C of the temperature of described making beating.Preferably 1 hour~3 hours time of described making beating, such as 1 is little When.Described being filtered, washed and dried can be using the conventional method of this generic operation in this area.The preferred vacuum of described drying It is dried;Preferably 50 DEG C~60 DEG C of described vacuum drying temperature;The described vacuum drying time preferably 1 hour~24 is little When, further preferred 6 hours~12 hours;Described vacuum drying pressure preferably -0.08MPa~-0.1MPa.
Without prejudice to the field on the basis of common sense, above-mentioned each optimum condition, can combination in any, obtain final product the present invention each preferably Example.
Agents useful for same of the present invention and raw material are all commercially available.
In the present invention, described room temperature refers to ambient temperature, is 10 DEG C~35 DEG C.
The positive effect of the present invention is:The preparation method of the present invention is simple to operate, post processing is easy, high income, Prepared emtricitabine product purity height can reach crude drug standard, and (HPLC purity is more than 99.60%, and maximum single contaminant is little In 0.10%), low production cost, be suitable for industrialized production.
Specific embodiment
Further illustrate the present invention below by the mode of embodiment, but therefore do not limit the present invention to described reality Apply among a scope.The experimental technique of unreceipted actual conditions in the following example, conventionally and condition, or according to business Product description selects.
Embodiment 1:The preparation method (referenced patent CN200410023745.6, embodiment 1) of emtricitabine intermediate III
720g emtricitabine intermediate compound IV adds 7.2L dichloromethane, 20mLDMF, is cooled to 0~5 DEG C, Deca protochloride Sulfone 192mL is in the solution of 1.2L dichloromethane.Stir 2 hours at 10~15 DEG C, concentrating under reduced pressure, be subsequently adding 2.2L toluene cold Stand-by.324g 5-flurocytosine, 12g ammonium sulfate, 600mL hexamethyl two silicon substrate amine alkane, add 960mL toluene, are heated to reflux 1~2 hour.Somewhat it is cooled to less than 90 DEG C, Deca 350mL triethylamine, it is heated to backflow but inviolent.It is added dropwise to above-mentioned preparation Chloro thing solution, washed with 240mL toluene.Backflow 2~3 hours, is cooled to 30~35 DEG C, Deca 180mL triethylamine is in water In solution 2.9L, be cooled to 15~20 DEG C, stir 1 hour, Deca normal heptane 2.9L, stir 16 hours, filter, washing, do Emtricitabine intermediate III, 504g, yield 50.5%, HPLC purity 98.17% is obtained after dry.
Embodiment 2:The preparation method of emtricitabine hydrochlorate II crude product
420g emtricitabine intermediate III (HPLC purity 98.17%) adds potassium dihydrogen phosphate 540g, water 600mL, ethanol 300mL, 10~15 DEG C of Deca 160g sodium borohydrides in 800mL water and 8mL mass percent be 25% sodium hydrate aqueous solution (described mass percent refers to that the quality of sodium hydroxide accounts for the percentage ratio of sodium hydrate aqueous solution gross mass), at 20~30 DEG C Stirring 2~3 hours, being adjusted to pH with the hydrochloric acid of 1mol/L is 4~5, stirs 0.5 hour, then the sodium hydroxide water with 2mol/L It is 7 that solution is adjusted to pH, is extracted three times with toluene and water.Organic faciess discard for menthol.Aqueous phase is concentrated to dryness to obtain grace after separating His shore I crude product (HPLC purity 95.73%) bent.
300g emtricitabine I crude product (HPLC purity 95.73%) uses isopropanol 3L to dissolve, Deca 0.6L at 10~20 DEG C 2N isopropanol hydrogen chloride solution, adds for about 20~30 minutes, and after adding, at 10~20 DEG C, stirring separates out emtricitabine salt in 2 hours Hydrochlorate II.Filter, filter cake isopropanol (1L) drip washing twice, 60 DEG C of vacuum (pressure is -0.08MPa~-0.1MPa) dry 4~ Obtain within 5 hours 275g emtricitabine hydrochlorate II crude product.Yield 93.6%, HPLC purity 99.03%.
Embodiment 3:The preparation method of emtricitabine hydrobromate II ' crude product
42g emtricitabine intermediate III (HPLC purity 98.17%) adds potassium dihydrogen phosphate 54g, water 60mL, ethanol 30mL, 10~15 DEG C of Deca 16g sodium borohydrides in 80mL water and 1mL mass percent be 25% sodium hydrate aqueous solution (institute The mass percent stated refers to that the quality of sodium hydroxide accounts for the percentage ratio of sodium hydrate aqueous solution gross mass), stir at 20~30 DEG C Mix 2~3 hours, being adjusted to pH with the hydrochloric acid of 1mol/L is 4~5, stirs 0.5 hour, more water-soluble with the sodium hydroxide of 2mol/L It is 7 that liquid is adjusted to pH, is extracted three times with toluene and water.Organic faciess discard for menthol.Aqueous phase is concentrated to dryness to obtain grace song after separating His shore I crude product (HPLC purity 94.67%).
30g emtricitabine I crude product (HPLC purity 94.67%) uses isopropanol 300mL to dissolve, Deca at 10~20 DEG C 60mL 2N ethanol hydrogen bromide solution, adds for about 2~3 minutes, and after adding, at 10~20 DEG C, stirring separates out emtricitabine in 2 hours Hydrobromate II '.Filter, twice, 60 DEG C of vacuum (pressure is -0.08MPa~-0.1MPa) dry 4 for filter cake isopropanol drip washing Obtain within~5 hours 28.6g emtricitabine hydrobromate II ' crude product.Yield 84.2%, HPLC purity 98.66%.
Embodiment 4:The process for purification of emtricitabine hydrochlorate II
200g emtricitabine hydrochlorate II (HPLC purity 99.03%), adds methanol 1L, is heated to 55~65 DEG C of dissolvings, Add diisopropyl ether 1.6L, cool to 10~15 DEG C, and stir 1 hour, the speed of stirring is 60 revs/min, filters, uses isopropyl Ether 300mL washes twice.At -0.08~-0.1MPa and 50~60 DEG C, vacuum drying obtains emtricitabine hydrochloric acid in 4~8 hours Salt II, 178g, HPLC purity 99.96%, yield 89.0%.
Embodiment 5:The process for purification of emtricitabine hydrochlorate II
10g emtricitabine hydrochlorate II (HPLC purity 99.03%), adds ethanol 60mL, is heated to 55~65 DEG C of dissolvings, Add ethyl acetate 100mL, cool to 10~15 DEG C, and stir 1 hour, the speed of stirring is 80 revs/min, filters, and uses Ethyl acetate 30mL washes twice.At -0.08~-0.1MPa and 50~60 DEG C, vacuum drying obtains emtricitabine in 4~8 hours Hydrochlorate II, 8.74g, HPLC purity 99.90%, yield 87.4%.
Embodiment 6:The process for purification of emtricitabine hydrochlorate II
10g emtricitabine hydrochlorate II (HPLC purity 99.03%), add isopropanol 80mL, be heated to 55~65 DEG C molten Solution, adds isopropyl acetate 80mL, cools to 10~15 DEG C, and stir 1 hour, and the speed of stirring is 100 revs/min, mistake Filter, is washed twice with isopropyl acetate 30mL.It is vacuum dried at -0.08~-0.1MPa and 50~60 DEG C and obtain for 4~8 hours Emtricitabine hydrochlorate II, 8.66g, HPLC purity 99.95%, yield 86.6%.
Embodiment 7:The process for purification of emtricitabine hydrochlorate II
10g emtricitabine hydrochlorate II (HPLC purity 99.03%), adds ethanol 60mL, is heated to 55~65 DEG C of dissolvings, Add 2- methyltetrahydrofuran 80mL, cool to 10~15 DEG C, and stir 1 hour, the speed of stirring is 120 revs/min, mistake Filter, is washed twice with 2- methyltetrahydrofuran 30mL.It is vacuum dried 4~8 hours at -0.08~-0.1MPa and 50~60 DEG C Obtain emtricitabine hydrochlorate II, 8.37g, HPLC purity 99.81%, yield 83.7%.
Embodiment 8:The process for purification of emtricitabine hydrochlorate II
10g emtricitabine hydrochlorate II (HPLC purity 99.03%), add tert-butyl alcohol 100mL, be heated to 60~70 DEG C molten Solution, cools to 5~10 DEG C, and stirs 1 hour, and the speed of stirring is 90 revs/min, filters, with being cooled to 0 DEG C of the tert-butyl alcohol 30mL washes twice.At -0.08~-0.1MPa and 50~60 DEG C, vacuum drying obtains emtricitabine hydrochlorate in 4~8 hours II, 8.09g, HPLC purity:99.83%, yield 80.9%.
Embodiment 9:The process for purification of emtricitabine hydrobromate II '
23.1g emtricitabine hydrobromate II ' (HPLC purity 98.66%), adds methanol 116mL, is heated to 55~65 DEG C dissolving, add diisopropyl ether 185mL, cool to 10~15 DEG C, and stir 1 hour, filter, wash two with diisopropyl ether 35mL Secondary.It is vacuum dried at -0.08~-0.1MPa and 50~60 DEG C and obtain within 4~8 hours emtricitabine hydrogen bromide II, 20.3g, HPLC purity 99.92%, yield 87.9%.
Embodiment 10:The preparation method of emtricitabine I
170g emtricitabine hydrochlorate II (HPLC purity 99.96%), add methanol 850mL, be heated to 50~60 DEG C molten Solution, cools to 15~25 DEG C, is added dropwise to triethylamine 62g and adds for about 6~8 minutes.Stir 1 hour at 15~25 DEG C, concentrated in vacuo Remove methanol, add 700mL dichloromethane, stir 1 hour at 20~25 DEG C, filter, filter cake adds 500mL dichloromethane, 20~25 DEG C are stirred 1 hour, filter, and filter cake is washed twice with 250mL dichloromethane.At -0.08~-0.1MPa and 50~60 DEG C Lower vacuum drying obtains 138g emtricitabine I, HPLC purity 99.94%, maximum single contaminant 0.04%, calcination for 6~12 hours Residue 0.03%, yield 93.2%.
Embodiment 11:The preparation method of emtricitabine I
8.5g emtricitabine hydrochlorate II (HPLC purity 99.81%), add methanol 68mL, be heated to 50~60 DEG C molten Solution, cools to 15~25 DEG C, is added dropwise to N, N- diisopropyl ethyl amine 4.65g, adds within about 20 seconds~30 seconds.Stir at 15~25 DEG C Mix 1 hour, removal methanol concentrated in vacuo, add 35mL dichloromethane, stir 1 hour at 20~25 DEG C, filter, filter cake adds 25mL dichloromethane, stirs 1 hour at 20~25 DEG C, filters, and filter cake is washed twice with 13mL dichloromethane.- 0.08~- At 0.1MPa and 50~60 DEG C, vacuum drying obtains 6.76g emtricitabine I, HPLC purity 99.87%, maximum list for 6~12 hours One impurity 0.05%, ignition residue 0.04%, yield 91.3%.
Embodiment 12:The preparation method of emtricitabine I
20g emtricitabine hydrobromate II ' (HPLC purity 99.92%), adds methanol 160mL, is heated to 50~60 DEG C Dissolving, cools to 15~25 DEG C, is added dropwise to N, N- diisopropyl ethyl amine 10.94g, about 2 minutes~3 minutes.At 15~25 DEG C Stirring 1 hour, removal methanol concentrated in vacuo, add 82mL dichloromethane, stir 1 hour at 20~25 DEG C, filter, filter cake adds 59mL dichloromethane, stirs 1 hour at 20~25 DEG C, filters, and filter cake is washed twice with 30mL dichloromethane.- 0.08~- At 0.1MPa and 50~60 DEG C, vacuum drying obtains 13.4g emtricitabine I, HPLC purity 99.92%, maximum list for 6~12 hours One impurity 0.04%, ignition residue 0.05%, yield 88.9%.
Embodiment 13:The preparation method of emtricitabine hydrochlorate II crude product
300g emtricitabine I crude product (HPLC purity 85.21%) uses isopropanol 3L to dissolve, Deca 0.6L at 10~20 DEG C 2mol/L isopropanol hydrogen chloride solution, adds for about 20~30 minutes, after adding at 10~20 DEG C stirring separate out within 2 hours grace bent he Shore hydrochlorate II.Filter, twice, 60 DEG C of vacuum (pressure is -0.08MPa~-0.1MPa) are dried for filter cake isopropanol (1L) drip washing Do and obtain within 4~5 hours 206g emtricitabine hydrochlorate II crude product.Yield 79.2%, HPLC purity 98.89%.
Embodiment 14:The preparation method of emtricitabine hydrochlorate II crude product
300g emtricitabine I crude product (HPLC purity 90.36%) uses isopropanol 3L to dissolve, Deca 0.6L at 10~20 DEG C 2mol/L isopropanol hydrogen chloride solution, adds for about 20~30 minutes, after adding at 10~20 DEG C stirring separate out within 2 hours grace bent he Shore hydrochlorate II.Filter, twice, 60 DEG C of vacuum (pressure is -0.08MPa~-0.1MPa) are dried for filter cake isopropanol (1L) drip washing Do and obtain within 4~5 hours 223g emtricitabine hydrochlorate II crude product.Yield 85.8%, HPLC purity 98.95%.
Comparative example 1:The original preparation method (with reference to patent documentation US5814639 and US5914331) of emtricitabine I
200~300 mesh silica fillers of 200g, add 3g emtricitabine I crude product (HPLC purity 98.17%), with containing Dichloromethane solution 400~the 500mL of 10%~15% methanol rinses, and leacheate is concentrated in vacuo.With recrystallisation from isopropanol, obtain 0.91g emtricitabine finished product, yield 35.0%, HPLC purity 99.74%, maximum single contaminant 0.08%.
Comparative example 2:Original preparation method (the list of references of emtricitabine I:《Chinese pharmaceutical chemistry magazine》, 2002 Year, volume 12, page 34 and《Chinese Journal of Pharmaceuticals》2005, volume 36, page 589)
3g emtricitabine I crude product (HPLC purity 98.17%), uses methanol/isopropanol repeated recrystallize, obtains 2.23g grace His shore finished product bent, yield 85.8%, HPLC purity 99.52%, maximum single contaminant 0.39%.Ignition residue 0.75% is (discontented The requirement 0.1% of sufficient API).
From comparative example 1, in the preparation method prior art of emtricitabine I, such as patent documentation US5814639 and US5914331 is reported, and forms water miscible emtricitabine I after intermediate III reduction, by recrystallization, inorganic salt is bent with grace His shore I separation yield is low, needs to carry out column chromatography for separation except inorganic salt, needs silica gel amount and relatively more (the emtricitabine I of quantity of solvent Hundred times, see comparative example 1), production cost is high, is not suitable for industrialized production (see comparative example 1).
From comparative example 2, in the preparation method prior art of emtricitabine I, such as periodical literature《Chinese medicine Learn magazine》, 2002, volume 12, page 34 and《Chinese Journal of Pharmaceuticals》2005, volume 36, page 589 reported, intermediate III Form water miscible emtricitabine I after reduction, do not carry out the product purity that column chromatography for separation then obtains and do not reach crude drug requiring (see comparative example 2) is it is difficult to industrialization and cost is also high.

Claims (10)

1. a kind of preparation method of emtricitabine halogen acid salt is it is characterised in that it comprises the following steps:In alcohols solvent, will Emtricitabine crude product and hydrogen halides carry out salt-forming reaction, obtain emtricitabine halogen acid salt;Described emtricitabine crude product HPLC purity be more than 85.0%;Described hydrogen halides are hydrogen chloride, hydrogen bromide or hydrogen iodide;X is chlorine, bromine or iodine;
2. emtricitabine halogen acid salt as claimed in claim 1 preparation method it is characterised in that:In described emtricitabine In the preparation method of halogen acid salt, described alcohols solvent is one or more of methanol, ethanol, isopropanol and tert-butyl alcohol;
And/or,
In the preparation method of described emtricitabine halogen acid salt, described emtricitabine crude product and described alcohols solvent Mass volume ratio value is 1: 1g/mL~1: 30g/mL;
And/or,
In the preparation method of described emtricitabine halogen acid salt, described hydrogen halides are hydrogen chloride or hydrogen bromide;
And/or,
In the preparation method of described emtricitabine halogen acid salt, described hydrogen halides are rubbed with described emtricitabine crude product Your ratio is 1~1.2;
And/or,
In the preparation method of described emtricitabine halogen acid salt, the temperature of described salt-forming reaction is -20 DEG C~30 DEG C;
And/or,
In the preparation method of described emtricitabine halogen acid salt, the time of described salt-forming reaction is 1 hour~10 hours.
3. emtricitabine halogen acid salt as claimed in claim 2 preparation method it is characterised in that:
In the preparation method of described emtricitabine halogen acid salt, described alcohols solvent is isopropanol;
And/or,
In the preparation method of described emtricitabine halogen acid salt, described emtricitabine crude product and described alcohols solvent Mass volume ratio value is 1: 5g/mL~1: 20g/mL;
And/or,
In the preparation method of described emtricitabine halogen acid salt, it is hydrogen chloride gas or hydrogen chloride when using hydrogen chloride Alcoholic solution form;
And/or,
In the preparation method of described emtricitabine halogen acid salt, it is the shape of the alcoholic solution of hydrogen bromide when using hydrogen bromide Formula;
And/or,
In the preparation method of described emtricitabine halogen acid salt, described hydrogen halides are rubbed with described emtricitabine crude product Your ratio is 1~1.1;
And/or,
In the preparation method of described emtricitabine halogen acid salt, the temperature of described salt-forming reaction is 0 DEG C~30 DEG C;
And/or,
In the preparation method of described emtricitabine halogen acid salt, the time of described salt-forming reaction is 1 hour~5 hours.
4. emtricitabine halogen acid salt as claimed in claim 3 preparation method it is characterised in that:
In the preparation method of described emtricitabine halogen acid salt, described emtricitabine crude product and described alcohols solvent Mass volume ratio value is 1: 10g/mL;
And/or,
In the preparation method of described emtricitabine halogen acid salt, when using ethanolic hydrogen chloride solution, described hydrogen chloride alcohol The concentration of solution is 1mol/L~3mol/L;
And/or,
In the preparation method of described emtricitabine halogen acid salt, when using hydrogen bromide alcoholic solution, described hydrogen bromide alcohol The concentration of solution is 1mol/L~3mol/L;
And/or,
In the preparation method of described emtricitabine halogen acid salt, described hydrogen halides are rubbed with described emtricitabine crude product Your ratio is 1.0;
And/or,
In the preparation method of described emtricitabine halogen acid salt, the temperature of described salt-forming reaction is 10 DEG C~20 DEG C;
And/or,
In the preparation method of described emtricitabine halogen acid salt, the time of described salt-forming reaction is 2 hours.
5. emtricitabine halogen acid salt as claimed in claim 1 preparation method it is characterised in that:
The preparation method of described emtricitabine halogen acid salt, using following steps:The alcoholic solution of hydrogen halides is added to grace bent In the solution that his shore crude product is formed with alcohols solvent, carry out salt-forming reaction, obtain emtricitabine halogen acid salt;
And/or,
The preparation method of described emtricitabine halogen acid salt, including following post-processing step:After reaction terminates, filter, wash, It is dried to obtain emtricitabine halogen acid salt.
6. emtricitabine halogen acid salt as claimed in claim 5 preparation method it is characterised in that:Described emtricitabine hydrogen The preparation method of halate, further includes following post-processing step:The emtricitabine obtaining halogen acid salt is recrystallized to give Emtricitabine halogen acid salt after purification.
7. emtricitabine halogen acid salt as claimed in claim 6 preparation method it is characterised in that:
In the post-processing step that the preparation method of described emtricitabine halogen acid salt further includes, described recrystallization is adopted Solvent is alcohols solvent, alcohols solvent and the mixed solvent of ether solvent or the mixing of alcohols solvent and esters solvent are molten Agent;
And/or,
In the post-processing step that the preparation method of described emtricitabine halogen acid salt further includes, described recrystallization Temperature is 50 DEG C~80 DEG C;
And/or,
In the post-processing step that the preparation method of described emtricitabine halogen acid salt further includes, described recrystallization is adopted With following steps 1 or step 2:
Step 1:Emtricitabine halogen acid salt is dissolved in alcohols solvent, adds ether solvent or esters solvent, cooling analysis Crystalline substance obtains emtricitabine halogen acid salt after purification;
Step 2:Emtricitabine halogen acid salt is dissolved in alcohols solvent, then cooling crystallization obtains emtricitabine hydrogen after purification Halate.
8. emtricitabine halogen acid salt as claimed in claim 7 preparation method it is characterised in that:
In the post-processing step that the preparation method of described emtricitabine halogen acid salt further includes, described alcohols is molten The mixed solvent of the mixed solvent of agent, alcohols solvent and ether solvent or alcohols solvent and esters solvent and described emtricitabine The mass volume ratio value of halogen acid salt is 1: 1g/mL~1: 30g/mL;
And/or,
In the post-processing step that the preparation method of described emtricitabine halogen acid salt further includes, described alcohols solvent For one or more of methanol, ethanol, isopropanol and tert-butyl alcohol;
And/or,
In the post-processing step that the preparation method of described emtricitabine halogen acid salt further includes, described ether solvent For one or more of diisopropyl ether, dioxane, oxolane, 2- methyltetrahydrofuran and n-butyl ether;
And/or,
In the post-processing step that the preparation method of described emtricitabine halogen acid salt further includes, described esters solvent For ethyl acetate and/or isopropyl acetate;
And/or,
In the post-processing step that the preparation method of described emtricitabine halogen acid salt further includes, when adopting alcohols solvent During with the mixed solvent of ether solvent, described ether solvent is 1~2 with the volume ratio of described alcohols solvent;
And/or,
In the post-processing step that the preparation method of his shore halogen acid salt of the song described in grace further includes, when adopting alcohols solvent During with the mixed solvent of esters solvent, described esters solvent is 1~2 with the volume ratio of described alcohols solvent;
And/or,
In the post-processing step that the preparation method of described emtricitabine halogen acid salt further includes, described recrystallization Temperature is 55 DEG C~70 DEG C;
And/or,
In step 1 or step 2, the temperature of described dissolving is 50 DEG C~80 DEG C;
And/or,
In step 1 or step 2, the temperature of described cooling crystallization is 0 DEG C~20 DEG C;
And/or,
In step 1 or step 2, the time of described cooling crystallization is 1 hour~5 hours;
And/or,
In step 1 or step 2, described dissolving and cooling crystallization are carried out under conditions of stirring.
9. emtricitabine halogen acid salt as claimed in claim 8 preparation method it is characterised in that:
In the post-processing step that the preparation method of described emtricitabine halogen acid salt further includes, described alcohols is molten The mixed solvent of the mixed solvent of agent, alcohols solvent and ether solvent or alcohols solvent and esters solvent and described emtricitabine The mass volume ratio value of halogen acid salt is 1: 2g/mL~1: 20g/mL;
And/or,
In the post-processing step that the preparation method of described emtricitabine halogen acid salt further includes, when adopting alcohols solvent During with the mixed solvent of ether solvent, described ether solvent is 1.6 or 1.3 with the volume ratio of described alcohols solvent;
And/or,
In the post-processing step that the preparation method of described emtricitabine halogen acid salt further includes, when adopting alcohols solvent During with the mixed solvent of esters solvent, described esters solvent is 1 or 1.7 with the volume ratio of described alcohols solvent;
And/or,
In the post-processing step that the preparation method of described emtricitabine halogen acid salt further includes, described recrystallization Temperature is 55 DEG C~65 DEG C or 60 DEG C~70 DEG C;
And/or,
In step 1 or step 2, the temperature of described dissolving is 55 DEG C~70 DEG C;
And/or,
In step 1 or step 2, the temperature of described cooling crystallization is 5 DEG C~15 DEG C;
And/or,
In step 1 or step 2, the time of described cooling crystallization is 1 hour~3 hours;
And/or,
In step 1 or step 2, when described dissolving and cooling crystallization are carried out under conditions of stirring, the speed of described stirring Spend for 60~120 revs/min.
10. emtricitabine halogen acid salt as claimed in claim 9 preparation method it is characterised in that:
In the post-processing step that the preparation method of described emtricitabine halogen acid salt further includes, described alcohols is molten The mixed solvent of the mixed solvent of agent, alcohols solvent and ether solvent or alcohols solvent and esters solvent and described emtricitabine The mass volume ratio value of halogen acid salt is 1: 5g/mL, 1: 10g/mL, 1: 13g/mL, 1: 14g/mL or 1: 16g/mL;
And/or,
In the post-processing step that the preparation method of described emtricitabine halogen acid salt further includes, described alcohols solvent Mixed solvent with ether solvent is that methanol is molten with the mixing of 2- methyltetrahydrofuran with the mixed solvent of diisopropyl ether or ethanol Agent;
And/or,
In the post-processing step that the preparation method of described emtricitabine halogen acid salt further includes, described alcohols solvent Mixed solvent with esters solvent is that isopropanol is molten with the mixing of ethyl acetate with the mixed solvent of isopropyl acetate or ethanol Agent;
And/or,
In step 1 or step 2, the temperature of described dissolving is 55 DEG C~65 DEG C or 60 DEG C~70 DEG C;
And/or,
In step 1 or step 2, the temperature of described cooling crystallization is 5 DEG C~10 DEG C or 10 DEG C~15 DEG C;
And/or,
In step 1 or step 2, the time of described cooling crystallization is 1 hour;
And/or,
In step 1 or step 2, when described dissolving and cooling crystallization are carried out under conditions of stirring, the speed of described stirring Spend for 60 revs/min, 80 revs/min, 90 revs/min, 100 revs/min or 120 revs/min.
CN201610898062.8A 2016-10-14 2016-10-14 The preparation method of emtricitabine halogen acid salt Pending CN106478618A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610898062.8A CN106478618A (en) 2016-10-14 2016-10-14 The preparation method of emtricitabine halogen acid salt

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610898062.8A CN106478618A (en) 2016-10-14 2016-10-14 The preparation method of emtricitabine halogen acid salt

Publications (1)

Publication Number Publication Date
CN106478618A true CN106478618A (en) 2017-03-08

Family

ID=58270026

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610898062.8A Pending CN106478618A (en) 2016-10-14 2016-10-14 The preparation method of emtricitabine halogen acid salt

Country Status (1)

Country Link
CN (1) CN106478618A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106496208A (en) * 2016-10-19 2017-03-15 上海博志研新药物技术有限公司 The preparation method of emtricitabine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1313858A (en) * 1998-08-12 2001-09-19 三角药物公司 Manufacture of 1,3-oxathiolane nucleosides
WO2009084033A2 (en) * 2007-12-07 2009-07-09 Matrix Laboratories Limited Process for producing 5-fluoro-1-(2r,5s)-[2-(hydroxymethyl)-1,3-oxathiolan-5-yi]cytosine
WO2011107920A1 (en) * 2010-03-04 2011-09-09 Ranbaxy Laboratories Limited A process for stereoselective synthesis of 5-fluoro-1-(2r,5s)-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
CN105130972A (en) * 2015-08-04 2015-12-09 山东潍坊制药厂有限公司 Emtricitabine benzoate, preparation method thereof, and method of preparing emtricitabine from emtricitabine benzoate

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1313858A (en) * 1998-08-12 2001-09-19 三角药物公司 Manufacture of 1,3-oxathiolane nucleosides
WO2009084033A2 (en) * 2007-12-07 2009-07-09 Matrix Laboratories Limited Process for producing 5-fluoro-1-(2r,5s)-[2-(hydroxymethyl)-1,3-oxathiolan-5-yi]cytosine
WO2011107920A1 (en) * 2010-03-04 2011-09-09 Ranbaxy Laboratories Limited A process for stereoselective synthesis of 5-fluoro-1-(2r,5s)-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
CN105130972A (en) * 2015-08-04 2015-12-09 山东潍坊制药厂有限公司 Emtricitabine benzoate, preparation method thereof, and method of preparing emtricitabine from emtricitabine benzoate

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANDREW P. OSBORNE ET AL.: ""Immobilization of Cholesterol Esterase for Use in Multiple Batch Biotransformations to Prepare (-)- FTC (Emtricitabine)"", 《ORGANIC PROCESS RESEARCH & DEVELOPMENT》 *
刘新泳 等: "《实验室有机化合物制备与分离纯化技术》", 31 January 2011, 人民卫生出版社 *
马志龙 等: ""恩曲他滨合成路线图解"", 《中国医药工业杂志》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106496208A (en) * 2016-10-19 2017-03-15 上海博志研新药物技术有限公司 The preparation method of emtricitabine

Similar Documents

Publication Publication Date Title
CN101891647B (en) Preparation method for ubenimex
CN110291065A (en) A kind of new isoindoline derivative, its pharmaceutical composition and application
CN103539795A (en) Apixaban polymorph and preparation method thereof
CN104557911B (en) A kind of preparation method of levo-praziquantel
JP2018502909A5 (en)
CN104327138B (en) Preparation method of PSI-7977 intermediate compound
CN105968093A (en) Preparation method for trelagliptin succinate
CN105693691A (en) New crystal form and preparation method of highly pure trelagliptin
CN102796079B (en) A kind of preparation method of methanesulfonic acid fluorine imatinib
CN104774194B (en) deuterated hepatitis c virus inhibitors
WO2021098712A1 (en) Preparation method for chlorohomoserine alkyl ester
CN113200956B (en) Sulfabenzamide derivative and preparation method and application thereof
CN105859686B (en) Refining method of dabigatran etexilate free alkali
CN106478618A (en) The preparation method of emtricitabine halogen acid salt
CN106496208A (en) The preparation method of emtricitabine
CN106608853B (en) The preparation method of dipeptidy peptidase in inhibitors
CN105622538A (en) One-pot high-yielding preparation of cetilistat
TWI445711B (en) Improved method for preparation of adefovir dipivoxil
CN106699812A (en) Method for preparation and purification of tenofovir prodrug
CN106977543A (en) The preparation technology of improved Suo Feibuwei intermediates
CN104230818B (en) The improvement preparation method of ticagrelor midbody
CN102372690B (en) Intermediate for synthesizing imatinib and application of intermediate in imatinib synthesis
CN105272921A (en) Method for preparing Ceritinib and intermediate compound of Ceritinib
CN104098547B (en) A kind of process for purification of Fasudic hydrochloride
WO2022110612A1 (en) Preparation method for s-configuration phenylethylamine hydrochloride compound

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20180926

Address after: 201203 A679-04 room 2, 351 Guo Shou Jing Road, China (Shanghai) free trade pilot area

Applicant after: Shanghai Bozhi Yanxin Pharmaceutical Technology Co.,Ltd.

Address before: 201203 Shanghai, China (Shanghai) free trade pilot area, Cai Lun Road, room 781, 213.

Applicant before: Shanghai Li Tai Pharmaceutical Technology Co., Ltd.

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20170308